Shigenari Nukaga

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Shigenari Nukaga, Hiroyuki Yasuda, Katsuya Tsuchihara et al. · Cancer Research · 2017 · 173 citations

<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer

Toshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani et al. · Oncotarget · 2015 · 157 citations · Full text

Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer

Masayoshi Miyawaki, Hiroyuki Yasuda, Tetsuo Tani et al. · Molecular Cancer Research · 2016 · 71 citations · Full text

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations

Keita Masuzawa, Hiroyuki Yasuda, Junko Hamamoto et al. · Oncotarget · 2017 · 55 citations · Full text

Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations

Hanako Hasegawa, Hiroyuki Yasuda, Junko Hamamoto et al. · Lung Cancer · 2018 · 50 citations

Insertion Mutations, Cetuximab Combination Therapy, Non-small-cell Lung Cancer +8